Accessibility Menu
Biomind Labs logo

Biomind Labs(OTC) BMNDF

Current Price$0.05
Market Cap$3.88MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-80%
5 Year-94%
1 Year-50%
1 Month-58%
Biomind Labs last closing stock price
MetricPriceDate
Last closeUSD 0.052026-07-24
Biomind Labs stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+49.25%USD 0.032026-07-17
1 month-58.33%USD 0.122026-06-01
3 month-52.34%USD 0.102026-04-23
Year to date-56.14%USD 0.112025-12-30
1 year-50%USD 0.102025-06-25
3 year-90.38%USD 0.522023-04-04
5 year-93.82%USD 0.812021-07-15
Since inception-80%USD 0.252021-07-27

Biomind Labs Financials at a Glance

Market Cap

$3.88MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$893.84K

EPS (TTM)

-$0.01

P/E Ratio

-4.39

Dividend

$0.00

Beta (Volatility)

1.34 (Average)

Price

$0.05

Volume

151,682

Open

$0.06

Previous Close

$0.05

Daily Range

$0.05 - $0.06

52-Week Range

$0.01 - $0.15

Estimated Earnings Date

N/A

BMNDF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Biomind Labs

Biomind Labs Inc. is a biotechnology firm focused on developing innovative pharmaceutical therapies and advanced nanotech drug delivery systems. The company primarily targets psychiatric and neurological disorders, with several promising candidates in its pipeline.

Products and Services
  • BMND01: Phase II trials for depression treatment
  • BMND08: Phase II trials for anxiety and cognitive decline
  • Additional candidates for fibromyalgia, substance use disorders, and pain management
Growth Outlook
  • Strong pipeline with multiple candidates in Phase II clinical trials
  • Focus on addressing unmet needs in psychiatric and neurological disorders
  • Potential for significant market impact as therapies progress
Financial Highlights
  • Recent quarterly net income of -$102,659, reflecting ongoing investment in R&D
  • Trailing twelve months (TTM) revenue remains at $0, indicating early-stage development
  • Current ratio of 0.036 suggests a need for improved liquidity management
Biomind Labs Inc. is positioned in a rapidly evolving biotechnology sector, with a focus on addressing critical mental health issues. The company's commitment to research and development is evident in its diverse pipeline, which includes several candidates targeting various conditions. Despite the current lack of revenue, the ongoing clinical trials and innovative approach may present future opportunities for growth and market penetration. Investors may find the company's strategic focus on psychiatric and neurological disorders particularly compelling, given the increasing demand for effective treatments in these areas.
AI Generated • Jun 30, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

6

CEO

Alejandro Antalich

Website

biomindlabs.com

Headquarters

Vancouver, BC V7Y 1C6, CA

BMNDF Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

54.12%

Return on Capital

N/A

Return on Assets

-6212.83%

Earnings Yield

-22.78%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$3.88MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

77.57M

Volume

151.68K

Avg. Volume

2.99K

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$818.05K

EBITDA

-$820.53K

Operating Cash Flow

-$134.20K

Capital Expenditure

$0.32

Free Cash Flow

-$134.20K

Cash & ST Invst.

$14.39K

Total Debt

$786.78K

Biomind Labs Performance Analysis

Biomind Labs annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Biomind Labs sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Biomind Labs annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.04-33.6%
20232023-12-31USD -0.02-60.2%
20242024-12-31USD -0.00-78.6%
20252025-12-31USD -0.01223.5%
Biomind Labs sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-66.7%
Q32025-09-3013.3%
Q42025-12-31-469.2%
Q12026-03-3182.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

+100.0%

Gross Margin

0.00%

N/A

Market Cap

$3.88MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$775.72K

N/A

Employees

5

N/A

Net Income

-$102.66K

-53.8%

EBITDA

-$79.11K

-68.1%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$14.39K

+9620.9%

Total Debt

$786.78K

+25.2%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$786.78K

+25.2%

Return on Assets

-62.13%

N/A

Return on Invested Capital

45.11%

N/A

Free Cash Flow

-$65.04K

-14363.2%

Operating Cash Flow

-$65.04K

-14363.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
VCNXVaccinex, Inc.
$1.18+0.00%
ENZCEnzolytics Inc.
$0.00+0.00%
ISCOInternational Stem Cell Corporation
$0.31+10.71%
EVFMEvofem Biosciences, Inc.
$0.01-4.76%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
ONDSOndas
$7.80-0.02%
SOFISoFi Technologies
$16.46-0.01%
TAT&T
$24.13+0.05%

Questions About BMNDF

What is the current price of Biomind Labs?

Biomind Labs is trading at $0.05 per share.

What is the 52-week range for Biomind Labs?

Over the past 52 weeks, Biomind Labs has traded between $0.01 and $0.15.

How much debt does Biomind Labs have?

As of the most recent reporting period, Biomind Labs reported total debt of $786.78K.

How much cash does Biomind Labs have on hand?

Biomind Labs reported $14.39K in cash and cash equivalents in its most recent financial results.

What is Biomind Labs’s dividend yield?

Biomind Labs does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services